Matrix Laboratories Limited

Mylan Laboratories Limited

Madhuresh Kumar Sethi

Purna Chandra Ray

Om Dutt Tyagi

Gorantla Seeta Ramanjaneyulu

Bandari Mohan

Vijendra Singh Rawat

Yerramalla Raja Krishna

Bhairaiah Mara

Willem Robert Klaas Schoevaart

Vemula Lakshminarayana

Mamidi Srinivas

Michiel Christian Alexander Van Vliet

Sanjay Mahajan

Bhausaheb Chavhan

The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors. wherein X is hydrogen or hydroxy protecting group and Ris carboxyl protecting group.

Process for the preparation of intermediates of HMG-CoA reductase inhibitors

The present invention relates to a process for the preparation of pure Rabeprazole sulfoxide using the solvent mixture for the extraction steps and this invention further relates to the process for the preparation of amorphous Rabeprazole sodium using pure rabeprazole base in presence of aqueous NaOH and water miscible solvent and adding an anti-solvent.

Process for the preparation of pure rabeprazole

The present invention provides a process for the preparation of Olmesartan medoxomil by condensing the ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityl tetrazol-5-yl)phenyl]benzyl bromide to obtain ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate and then hydrolyzing ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methyl imidazole-5-carboxylate to obtain trityl Olmesartan dihydrate followed by reacting trityl Olmesartan dihydrate with 4-chloromethyl-5-methyl-2-oxo-1,3-dioxolene to obtain trityl Olmesartan medoxomil and then deprotecting trityl Olmesartan medoxomil to obtain Olmesartan medoxomil.

Process for the preparation of olmesartan medoxomil

Growing community of inventors

Hyderabad Telangana, India

Madhuresh Kumar Sethi